These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 33967966)
21. An update on the pathology of neuroendocrine tumors. Guadagno E; De Caro Mdel B; Insabato L Front Biosci (Schol Ed); 2016 Jan; 8(1):1-12. PubMed ID: 26709892 [TBL] [Abstract][Full Text] [Related]
22. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
23. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861 [TBL] [Abstract][Full Text] [Related]
24. [Ki67 and neuroendocrine tumors]. Couvelard A Ann Pathol; 2011 Nov; 31(5 Suppl):S55-6. PubMed ID: 22054461 [No Abstract] [Full Text] [Related]
25. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Klimstra DS; Modlin IR; Adsay NV; Chetty R; Deshpande V; Gönen M; Jensen RT; Kidd M; Kulke MH; Lloyd RV; Moran C; Moss SF; Oberg K; O'Toole D; Rindi G; Robert ME; Suster S; Tang LH; Tzen CY; Washington MK; Wiedenmann B; Yao J Am J Surg Pathol; 2010 Mar; 34(3):300-13. PubMed ID: 20118772 [TBL] [Abstract][Full Text] [Related]
26. Digestive neuroendocrine tumors: reclassifying of 26 cases according to 2010 who classification. Chaabane A; M'sakni I; Laabidi B; Bougrine F; Bouziani A Tunis Med; 2016 Oct; 94(8-9):580-586. PubMed ID: 28685792 [TBL] [Abstract][Full Text] [Related]
27. What is New in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing. Assarzadegan N; Montgomery E Arch Pathol Lab Med; 2021 Jun; 145(6):664-677. PubMed ID: 32233993 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia. Xu G; Wang Y; Zhang H; She X; Yang J Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448 [TBL] [Abstract][Full Text] [Related]
29. Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN). La Rosa S; Uccella S; Molinari F; Savio A; Mete O; Vanoli A; Maragliano R; Frattini M; Mazzucchelli L; Sessa F; Bongiovanni M Am J Surg Pathol; 2018 Nov; 42(11):1503-1512. PubMed ID: 30001239 [TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors. Özaslan E; Demir S; Karaca H; Güven K Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127 [TBL] [Abstract][Full Text] [Related]
33. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395 [TBL] [Abstract][Full Text] [Related]
34. Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. Diakatou E; Kaltsas G; Tzivras M; Kanakis G; Papaliodi E; Kontogeorgos G Endocr Pathol; 2011 Mar; 22(1):24-30. PubMed ID: 21287294 [TBL] [Abstract][Full Text] [Related]
36. [Neuroendocrine tumours of the alimentary tract--history and at present]. Mandys V Cesk Patol; 2009 Jul; 45(3):57-63. PubMed ID: 19764158 [TBL] [Abstract][Full Text] [Related]
37. Histopathology of NET: Current concepts and new developments. Schmitt AM; Blank A; Marinoni I; Komminoth P; Perren A Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):33-43. PubMed ID: 26971842 [TBL] [Abstract][Full Text] [Related]
38. [Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system]. Zhang XH; Lu XL; Wu N; Liu B; Wang FY; Zhang RS; Zhou XJ Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):191-6. PubMed ID: 23769440 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors. Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188 [TBL] [Abstract][Full Text] [Related]